Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(9):1356–1359. doi: 10.1038/bjc.1997.229

The influence of ifosfamide scheduling on acute nephrotoxicity in children.

M W English 1, R Skinner 1, A D Pearson 1, L Price 1, R Wyllie 1, A W Craft 1
PMCID: PMC2228242  PMID: 9155058

Abstract

Nephrotoxicity is a significant problem in children after treatment with ifosfamide. Acute changes in renal function were compared in 16 children receiving 9 g m(-2) of ifosfamide as a 72-h continuous infusion on one occasion and, on another course, divided into three 1-h infusions on consecutive days. Subclinical acute nephrotoxicity was demonstrated with both schedules, but there were no significant differences in severity.

Full text

PDF
1356

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. H., Ryan L., Elias A., Sherman D., Grier H. E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan;7(1):126–131. doi: 10.1200/JCO.1989.7.1.126. [DOI] [PubMed] [Google Scholar]
  2. Boddy A. V., English M., Pearson A. D., Idle J. R., Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer. 1996 Jun;32A(7):1179–1184. doi: 10.1016/0959-8049(96)00019-6. [DOI] [PubMed] [Google Scholar]
  3. Boddy A. V., Yule S. M., Wyllie R., Price L., Pearson A. D., Idle J. R. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer. 1995;31A(5):785–790. doi: 10.1016/0959-8049(95)00090-6. [DOI] [PubMed] [Google Scholar]
  4. Boddy A. V., Yule S. M., Wyllie R., Price L., Pearson A. D., Idle J. R. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. 1993 Aug 15;53(16):3758–3764. [PubMed] [Google Scholar]
  5. Caron H. N., Abeling N., van Gennip A., de Kraker J., Voûte P. A. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol. 1992;20(1):42–47. doi: 10.1002/mpo.2950200109. [DOI] [PubMed] [Google Scholar]
  6. De Schepper J., Hachimi-Idrissi S., Verboven M., Piepsz A., Otten J. Renal function abnormalities after ifosfamide treatment in children. Acta Paediatr. 1993 Apr;82(4):373–376. doi: 10.1111/j.1651-2227.1993.tb12700.x. [DOI] [PubMed] [Google Scholar]
  7. De Schepper J., Stevens G., Verboven M., Baeta C., Otten J. Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year-old child. Am J Pediatr Hematol Oncol. 1991 Spring;13(1):39–41. doi: 10.1097/00043426-199121000-00009. [DOI] [PubMed] [Google Scholar]
  8. Heney D., Wheeldon J., Rushworth P., Chapman C., Lewis I. J., Bailey C. C. Progressive renal toxicity due to ifosfamide. Arch Dis Child. 1991 Aug;66(8):966–970. doi: 10.1136/adc.66.8.966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marina N. M., Rodman J., Shema S. J., Bowman L. C., Douglass E., Furman W., Santana V. M., Hudson M., Wilimas J., Meyer W. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993 Mar;11(3):554–560. doi: 10.1200/JCO.1993.11.3.554. [DOI] [PubMed] [Google Scholar]
  10. Pratt C. B., Meyer W. H., Jenkins J. J., Avery L., McKay C. P., Wyatt R. J., Hancock M. L. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol. 1991 Aug;9(8):1495–1499. doi: 10.1200/JCO.1991.9.8.1495. [DOI] [PubMed] [Google Scholar]
  11. Rossi R., Danzebrink S., Hillebrand D., Linnenbürger K., Ullrich K., Jürgens H. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol. 1994;22(1):27–32. doi: 10.1002/mpo.2950220106. [DOI] [PubMed] [Google Scholar]
  12. Rossi R., Gödde A., Kleinebrand A., Riepenhausen M., Boos J., Ritter J., Jürgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994 Jan;12(1):159–165. doi: 10.1200/JCO.1994.12.1.159. [DOI] [PubMed] [Google Scholar]
  13. Rossi R., Helmchen U., Schellong G. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome--a report of two cases. Eur J Pediatr. 1992 May;151(5):384–387. doi: 10.1007/BF02113264. [DOI] [PubMed] [Google Scholar]
  14. Skinner R., Pearson A. D., Coulthard M. G., Skillen A. W., Hodson A. W., Goldfinch M. E., Gibb I., Craft A. W. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol. 1991;28(2):81–92. doi: 10.1007/BF00689694. [DOI] [PubMed] [Google Scholar]
  15. Skinner R., Pearson A. D., Price L., Coulthard M. G., Craft A. W. Nephrotoxicity after ifosfamide. Arch Dis Child. 1990 Jul;65(7):732–738. doi: 10.1136/adc.65.7.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Skinner R., Pearson A. D., Price L., Coulthard M. G., Craft A. W. The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer Suppl. 1992 Aug;18:S30–S35. [PMC free article] [PubMed] [Google Scholar]
  17. Skinner R., Sharkey I. M., Pearson A. D., Craft A. W. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993 Jan;11(1):173–190. doi: 10.1200/JCO.1993.11.1.173. [DOI] [PubMed] [Google Scholar]
  18. Suarez A., McDowell H., Niaudet P., Comoy E., Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol. 1991 Dec;9(12):2177–2182. doi: 10.1200/JCO.1991.9.12.2177. [DOI] [PubMed] [Google Scholar]
  19. al Sheyyab M., Worthington D., Beetham R., Stevens M. The assessment of subclinical ifosfamide-induced renal tubular toxicity using urinary excretion of retinol-binding protein. Pediatr Hematol Oncol. 1993 Apr-Jun;10(2):119–128. doi: 10.3109/08880019309016545. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES